Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital, South Australia, Australia.
Pediatr Infect Dis J. 2013 May;32(5):530-7. doi: 10.1097/INF.0b013e31827e92b7.
Varicella in children, although usually mild, can cause hospitalization and rarely death. This study examined patterns of hospitalized children with varicella, and associated varicella genotypes, in 4 tertiary children's hospitals throughout Australia before and after varicella vaccine was introduced.
We obtained coded data on discharge diagnoses from each hospital before (1999 to 2001) and after (2007 to 2010) varicella vaccine introduction in 2005, adding active surveillance to capture clinical features, complications and immunization history in the latter period. Varicella vesicles were swabbed, and genotyping of varicella strains was performed by real-time polymerase chain reaction amplification.
Overall, a 68% reduction in coded hospitalizations (varicella, 73.2% [P < 0.001]; zoster, 40% [P = 0.002]) occurred post-vaccine introduction. Of children with detailed clinical data (97 varicella and 18 zoster cases), 46 (40%) were immunocompromised. Only 6 of 32 (19%) age-eligible immunocompetent children were immunized. Complications, most commonly secondary skin infections (n = 25) and neurologic conditions (n = 14), occurred in 44% of children. There were no deaths; but 3 immunocompetent unimmunized children had severe multiple complications requiring intensive care. All strains genotyped were "wild-type" varicella, with Clade 1 (European origin) predominating.
After the introduction of varicella vaccine, coverage of greater than 80% at 2 years of age was achieved, with varicella hospitalizations reduced by almost 70%. Of hospitalized children age-eligible for varicella vaccine, 80% were unimmunized, including all cases requiring intensive care.
儿童水痘虽然通常症状较轻,但也可导致住院治疗,极少数情况下甚至会导致死亡。本研究在澳大利亚四家儿童医院,对水痘疫苗引入前后(2005 年)住院水痘患儿的发病模式和相关水痘基因型进行了研究。
我们从每家医院获得了疫苗引入前(1999 年至 2001 年)和后(2007 年至 2010 年)的出院诊断编码数据,并在后一时期通过主动监测来获取临床特征、并发症和免疫接种史。采集水痘疱疹拭子,并通过实时聚合酶链反应扩增进行水痘株的基因分型。
总体而言,疫苗引入后编码住院率(水痘住院率,73.2%[P<0.001];带状疱疹住院率,40%[P=0.002])下降了 68%。在有详细临床数据的儿童中(97 例水痘和 18 例带状疱疹病例),46 例(40%)存在免疫功能低下。仅有 6 名(19%)符合年龄条件的免疫功能正常儿童接受了免疫接种。44%的儿童出现并发症,最常见的是继发性皮肤感染(n=25)和神经系统疾病(n=14)。无死亡病例;但 3 例免疫功能正常且未接种疫苗的患儿发生严重多系统并发症,需要重症监护。所有基因分型的病毒株均为“野生型”水痘,以 1 型(欧洲起源)为主。
水痘疫苗引入后,2 岁儿童的接种覆盖率超过 80%,水痘住院率下降近 70%。在符合水痘疫苗接种年龄的住院患儿中,80%未接种疫苗,包括所有需要重症监护的病例。